EvolveImmune Therapeutics has filed a notice of an exempt offering of securities to raise $26,000,000.00 in New Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, EvolveImmune Therapeutics is raising $26,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Stephen Bloch played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About EvolveImmune Therapeutics
At EvolveImmune, we harness our Immunology First approach to create first-in-category cancer medicines to transform the lives of patients by delivering superior, long-term outcomes compared to current anti-cancer therapies. We are pioneers who rapidly translate discoveries into innovations and innovations into differentiated therapeutic solutions, to address the most significant unmet medical needs in oncology. We are based in Branford, CT and Farmington, CT.
To learn more about EvolveImmune Therapeutics, visit http://www.evolveimmune.com/
Contact:
Stephen Bloch, Chief Executive Officer
203-858-7389
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.